Celyad Oncology Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	14	8	29	16	11	79
Market Cap Growth	-30.43%	-74.20%	82.56%	41.33%	-85.61%	-13.96%
Enterprise Value	12	8	24	12	-1	76
Last Close Price	0.31	0.17	0.71	0.39	0.51	3.52
PE Ratio	17.28	9.17	-	-	-	-
PS Ratio	662.90	362.36	158.59	158.40	-	-
PB Ratio	5.71	3.12	57.72	2.56	2.65	1.82
P/TBV Ratio	5.75	3.14	60.45	2.58	2.96	10.00
EV/Sales Ratio	-	364.31	130.42	114.87	-	-
Debt / Equity Ratio	-	-	1.77	0.17	0.06	0.06
Net Debt / Equity Ratio	-0.70	-0.70	-6.45	-0.94	-2.82	-0.63
Net Debt / EBITDA Ratio	1.12	1.12	0.58	0.66	0.49	1.03
Net Debt / FCF Ratio	0.25	0.25	0.58	0.37	0.43	1.01
Asset Turnover	0.00	0.00	0.01	0.01	-	-
Quick Ratio	1.38	1.38	1.79	3.34	1.31	2.34
Current Ratio	1.92	1.92	2.29	3.79	1.42	2.48
Return on Equity (ROE)	56.33%	56.33%	-170.92%	-159.08%	-170.72%	-71.05%
Return on Assets (ROA)	-13.40%	-13.40%	-27.99%	-33.14%	-31.92%	-23.32%
Return on Capital Employed (ROCE)	-61.50%	-61.50%	-82.90%	-71.50%	-273.90%	-41.20%
Earnings Yield	5.96%	10.91%	-19.74%	-52.29%	-358.06%	-33.38%
FCF Yield	-	-90.68%	-19.26%	-99.65%	-246.08%	-33.97%
Buyback Yield / Dilution	-11.68%	-11.68%	-61.06%	-13.84%	-44.80%	-11.92%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.